Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 12/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24738588 | 1.00 | DGAT1 (0.42) | DGAT1KLKB1METTL3LMNAALDH1A1 | |
| SCHEMBL29137013 | 1.00 | DGAT1 (0.42) | DGAT1KLKB1METTL3LMNAALDH1A1 | |
| SCHEMBL29879552 | 1.00 | DGAT1 (0.42) | DGAT1KLKB1METTL3LMNAALDH1A1 | |
| SCHEMBL29136948 | 0.92 | KLKB1 (0.42) | DGAT1KLKB1METTL3ALDH1A1HTT | |
| SCHEMBL24739954 | 0.92 | KLKB1 (0.42) | DGAT1KLKB1METTL3ALDH1A1HTT | |
| SCHEMBL29879069 | 0.92 | KLKB1 (0.42) | DGAT1KLKB1METTL3ALDH1A1HTT | |
| SCHEMBL29136951 | 0.92 | KLKB1 (0.42) | DGAT1KLKB1METTL3ALDH1A1HTT | |
| SCHEMBL24737849 | 0.89 | KLKB1 (0.41) | DGAT1KLKB1METTL3ALDH1A1HTT | |
| SCHEMBL29879449 | 0.89 | KLKB1 (0.41) | DGAT1KLKB1METTL3ALDH1A1HTT | |
| SCHEMBL29136869 | 0.89 | KLKB1 (0.41) | DGAT1KLKB1METTL3ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |